摘要
目的评估对重度宫腔粘连术后予以阿司匹林、雌二醇片/雌二醇地屈孕酮片复合包装(商品名:芬吗通)联合治疗的有效性和安全性。方法60例重度宫腔粘连手术患者,采用抽签法分为对照组和治疗组,每组30例。对照组术后给予芬吗通治疗,治疗组术后给予阿司匹林联合芬吗通治疗。对比两组临床疗效、月经恢复效果、不良反应发生情况及治疗前后经血量、子宫内膜厚度、子宫动脉血流参数[血流指数(FI)、血管化血流指数(VFI)、血管化指数(VI)、搏动指数(PI)、阻力指数(RI)]、生活质量。结果与对照组对比,治疗组临床总有效率较高,但差异无统计学意义(P>0.05)。与对照组对比,治疗组月经恢复总有效率较高,但差异无统计学意义(P>0.05)。治疗组治疗后经血量(57.10±4.45)ml多于对照组的(46.13±4.40)ml,子宫内膜厚度(9.79±1.36)mm大于对照组的(8.26±1.18)mm(P<0.05)。两组不良反应发生率对比差异无统计学意义(P>0.05)。治疗组治疗后FI(28.20±1.70)、VFI(1.23±0.11)、VI(4.39±0.45)%明显高于对照组的(23.53±3.70)、(0.90±0.08)、(3.23±0.36)%,PI(1.28±0.15)、RI(1.03±0.10)明显低于对照组的(1.86±0.25)、(1.24±0.15)(P<0.05)。治疗组治疗后物质生活状态、心理功能、躯体功能、社会功能评分分别为(82.75±10.24)、(81.32±10.32)、(82.48±11.10)、(83.10±12.35)分,明显高于对照组的(74.16±11.18)、(75.68±10.28)、(73.78±11.28)、(73.57±12.20)分(P<0.05)。结论对重度宫腔粘连术后予以阿司匹林、芬吗通联合治疗具有较高的有效性和安全性,利于患者子宫内膜修复,促进月经恢复,改善生活质量,值得推广。
Objective To evaluate the efficacy and safety evaluation of aspirin combined with complex packing estradiol tablets/estradiol and dydrogesterone tablets(trade name:Femoston)in the repair of endometrium after severe intrauterine adhesion surgery.Methods 60 patients with severe intrauterine adhesions were divided into a control group and a treatment group by drawing lots,with 30 cases in each group.The control group was treated with Femoston,and the treatment group was treated with aspirin and Femoston.Both groups were compared in terms of clinical efficacy,menstrual recovery effect,occurrence of adverse reactions and menstrual blood volume,endometrial thickness,uterine artery blood flow parameters[flow index(FI),vascularized flow index(VFI),vascularization index(VI),pulsatility index(PI),resistance index(RI)],and quality of life before and after the treatment.Results Compared with the control group,the total clinical effective rate of the treatment group was higher,but the difference was not statistically significant(P>0.05).Compared with the control group,the total effective rate of menstrual recovery in the treatment group was higher,but the difference was not statistically significant(P>0.05).After treatment,the treatment group had more menstrual blood volume of(57.10±4.45)ml than(46.13±4.40)ml in the control group,and greater endometrial thickness of(9.79±1.36)mm than(8.26±1.18)mm in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the treatment group had FI of(28.20±1.70),VFI of(1.23±0.11)and VI of(4.39±0.45)%,which were significantly higher than(23.53±3.70),(0.90±0.08)and(3.23±0.36)%in the control group;the treatment group had PI of(1.28±0.15)and RI of(1.03±0.10),which were significantly lower than(1.86±0.25)and(1.24±0.15)in the control group(P<0.05).After treatment,the scores of material life status,psychological function,physical function and social function in the treatment group were(82.75±10.
作者
陈燕飞
CHEN Yan-fei(Gynecology Department,Linyi Maternal and Child Health Hospital,Linyi 276016,China)
出处
《中国现代药物应用》
2024年第10期21-25,共5页
Chinese Journal of Modern Drug Application
